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Development of bioluminescence resonance energy transfer (BRET) based genetic sensors
for sensing biological functions such as protein–protein interactions (PPIs) in vivo has a
special value in measuring such dynamic events at their native environment. Since its
inception in the late nineties, BRET related research has gained significant momentum in
terms of adding versatility to the assay format and wider applicability where it has been
suitably used. Beyond the scope of quantitative measurement of PPIs and protein dimer-
ization, molecular imaging applications based on BRET assays have broadened its scope
for screening pharmacologically important compounds by in vivo imaging as well. In this
mini-review we focus on an in-depth analysis of engineered BRET systems developed and
their successful application to cell-based assays as well as in vivo non-invasive imaging in
live subjects.
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INTRODUCTION
In the post-genomic era, rapid functional evaluation of protein–
protein interactions (PPIs), protein phosphorylation, or protease
function, which play a key role in various cellular processes such
as signal transduction, cell division, transport, etc., in live cell con-
dition is essential. Moreover, the study of such PPIs in normal
and diseased cells can help shed light in the understanding of
the diseases and to develop suitable therapies. For a long time,
conventional biochemical assays like co-immunoprecipitation (1,
2), gel-filtration chromatography (3), sandwich enzyme-linked
immunosorbent assay (ELISA) (4), etc., have been used in the
investigation of PPIs. These assays though successful, do not suf-
fice as imaging probes because they: (i) are essentially endpoint
measurements, (ii) fail to provide spatio-temporal information
on specific PPIs, (iii) require mechanical, chaotropic, or detergent
based cell lyses, which may alter native PPIs in some cases (5, 6),
(iv) are insensitive to transient interactions that regulate certain
cellular processes, and (v) have little or no utility for in vivo imag-
ing in live subjects. To overcome these limitations, non-invasive
imaging approaches such as bioluminescence resonance energy
transfer (BRET) have been developed over the last decade, which
allow the study of PPIs in their native environment and are capa-
ble of providing a unified platform that can be translated from
cell culture-based assays to the imaging of live subjects (6, 7). In
this mini-review, we will be exploring some hitherto unexplained
factors affecting the spectral pattern of several BRET systems and
their successful application to cell-based assays as well as in vivo
imaging of live subjects.
BIOPHYSICAL BASIS OF BRET
Bioluminescence resonance energy transfer is an intrinsic phe-
nomena occurring in the organisms Renilla reniformis and
Aequorea victoria. Exploiting the underlying principles of BRET
from nature, literatures demonstrating BRET biosensor applica-
tions started since the year 1999. The BRET phenomenon that
follows the Förster resonance energy transfer (RET) principle (8),
occurs between two proximally situated chromophores – a bio-
luminescent donor such as a luciferase protein and a fluorescent
protein (FP) acceptor with overlapping emission and excitation
spectra respectively. Following donor excitation upon substrate
addition, part of the electronic excitation energy of the donor is
dissipated due to random collisions with other molecules while
the remaining electronic relaxation energy is transferred to the
acceptor molecule through non-radiative dipole–dipole coupling.
Upon excitation, the acceptor molecule now emits its photonic
energy at its characteristic wavelength. This results in a decrease
in donor emission paralleled by an increase in acceptor emis-
sion. The strict dependence of BRET on the inter-chromophoric
distance (1–10 nm) makes it an appropriate “molecular yard-
stick” for determining PPIs. This is true, since the average pro-
tein radius is ∼5 nm, which means that a positive BRET signal
will only be detected if the two proteins come within ∼10 nm
of each other, a distance that is an indicator of direct inter-
action between the two proteins (9). However, absence of a
BRET signal does not necessarily mean that the two target pro-
teins do not interact with each other. Lack of a signal can be
accounted for by an unfavorable orientation between the donor
and acceptor dipoles. The BRET ratios can be calculated as per
Eqs. 1 and 2 (10).
BRET = BLemission
(
Acceptor λ
)− Cf × BLemission (Donor λ)
BLemission (Donorλ)
(1)
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where,
Cf =
BLemission
(
Acceptor λ
)
donor only
BLemission(Donor λ)donor only
(2)
In the above equation, BLemission is the average radiance mea-
sured at the donor (Donor λ) or acceptor (Acceptor λ) filters in
BRET-transfected or only donor transfected cells; the correction
factor (C f) represents the BRET signal detected from cells trans-
fected only with the donor plasmid. Upon subtracting this factor
from the overall BRET ratio, one can get an idea of the dynamic
range for a particular BRET pair. Moreover, since BRET-based
assays are ratiometric, any variability due to assay volume or cell
number variation or time point of measurement is nullified.
Until recently, the field of BRET-based biosensors has pre-
dominantly utilized two basic BRET systems, viz., BRET1 and
BRET2. Developed by Xu et al. the BRET1 system combinesRenilla
luciferase (RLuc) with enhanced yellow fluorescent protein (EYFP)
(11). However, the spectral resolution (separation of peak donor
and acceptor emission spectra) achieved in BRET1 is∼50 nm only,
which is considered suboptimal for macroscopic imaging (12, 13).
Another BRET system, named as BRET2, combining RLuc with a
UV-excitable GFP variant viz., GFP2 (14, 15) was developed, that
uses a coelenterazine analog-DeepBlueC™ (also known as coe-
lenterazine 400a or Clz400) substrate, which shifts the emission
maximum (Emmax ) of RLuc to 400 nm. GFP
2 excites at a maximum
(Exmax )of 396 nm and emits photons at 510 nm. This yields a much
larger spectral resolution of 110 nm and has enabled us to per-
form tissue-scale imaging using wideband filters for the first time
(16, 17). However, successful tissue imaging with higher sensitiv-
ity of cells located deep inside the animal body calls for the design
and development of BRET systems with more red-shifted emis-
sions. This is because, at wavelengths below 600 nm, particularly
in the blue-green regions of light, pigments like myoglobin and
hemoglobin absorb a significant fraction of the visible light (18).
EXPANSION OF BRET ASSAY FORMATS
In the past few years, improvisations in various components of
BRET such as luciferases, FPs, substrates, and instrumentations
have contributed to the remarkable expansion in the range of
BRET platforms available. Armed with these BRET vectors, the
progress of molecular imaging to live cells, animals, and plants
with varied applications has been made possible. With the advent
of engineered RLuc variants with an elevated photon output
and/or a red-shifted Emmax , viz., RLuc8 (Emmax 480 nm; four fold
increase in photon output compared to RLuc) (19) and RLuc8.6
(Emmax 535 nm; ∼6-fold increase in photon output compared
to RLuc) (20), new BRET systems in combination with FPs in
the orange and red regions of emission spectra were developed
(Figures 1A–D). Theoretically, the amplitude of donor emission
should always exceed the acceptor emission (Figures 1A,C). How-
ever, we noted that in the spectral profiles of some of these newly
developed BRET systems, the normalized amplitude at the donor
emission was lower in comparison to that at the acceptor emis-
sion (Figure 1B). For example, in the case of TagRFP-RLuc8, only
when Clz-v substrate was used (shifting the peak donor emis-
sion to 515 nm), the amplitude of TagRFP at 585 nm surpassed
RLuc8 emission. To explain this anomaly, a deeper understanding
of the RET principle is required. RET efficiency is essentially an
interplay between the spectral overlap integral of the donor emis-
sion and acceptor excitation spectra, in addition to the quantum
yield of the donor. We speculate that a donor bleed through signal
coupled with the high degree of spectral overlap between RLuc8
and TagRFP (upon the use of Clz-v) that favors maximum energy
transfer between the pair is detected at the acceptor filter, giving
an unnaturally high peak. On a different note, if one tries to define
the ideal BRET pair for tissue-scale imaging, it would be the one
that gives a high spectral resolution with minimally compromis-
ing the BRET ratio. Based on the data compiled from the BRET
systems available with us (Figure 1E), TurboFP and RLuc8.6-Clz
combination would be the ideal BRET partners for both in vitro
and in vivo imaging as they have a high BRET ratio (∼1.19) with
an equally high spectral separation of 100 nm.
BRET OPTIONS FOR STUDYING THE KINETICS OF PROTEIN
INTERACTIONS
A landmark development in the recruitment of BRET-based sys-
tems to capture the PPI kinetics was the creation of protected Clz
analogs. The problem associated with the use of normal Clz sub-
strates in live cells was their auto-oxidation, resulting in the loss of
peak signal within 2–3 min, which further drops to ∼50% within
17 min. Consequently the measurement of long-term PPI kinetics
is impossible using such substrates. To eliminate this problem, Levi
et al. (21) reported chemical modifications to protect the putative
oxygenation sites of Clz400 and demonstrated that depending on
the protective modifications, long-term BRET2 monitoring was
achievable. Similarly, another commercial source also developed
EnduRen™ substrate that can be used specifically for live cell imag-
ing (22). This is a protected form of coelenterazine-h with their
active sites blocked by esters or oxymethyl ethers that are only
released upon cleavage by intracellular hydrolytic enzymes. The
absence of active Clz-h in the media significantly reduces the sig-
nal attenuation due to background auto-oxidation and the half-life
of Clz-h increases. Moreover, a steady-state bioluminescence emis-
sion of EnduRen™ till about 24 h potentiates its use for monitoring
dynamic changes in PPIs from live cell conditions.
Another commonly used luciferase is the North American Fire-
fly luciferase (FLuc; Emmax 562 nm) (23). A codon-optimized
version of FLuc has been created by commercial sources for use
in mammalian cells. The relatively slower and stable emission
kinetics of its substrate, d-luciferin, makes it naturally suitable
for kinetic measurements from live environments, obviating the
need for any chemical modifications to its structure (24). FLuc has
been reported to be used in a BRET system in conjunction with
red FPs like DsRed (25) as well as with non-protein fluorophores
such as Cy3 and Cy3.5 (26). However, its bulky size of 61 kDa, an
obligate dependence on Mg2+ and ATP as its cofactors (27, 28) and
finally, a low spectral resolution with the BRET partners reported
so far, makes it a poor choice for BRET.
MULTIPLEXED BRET OPTIONS FOR CO-LATERAL
INTERACTION STUDIES
In addition to the simple PPIs assays, one might be interested
to monitor two concurrent dependent/independent PPI events
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FIGURE 1 | Various new generation of BRET pairs reported using
mutant Renilla luciferase proteins. (A) Represents TagRFP-RLuc8 pair
using normal coelenterazine (Clz) substrate. The bottom chart represents
normalized amplitude vs. wavelength measured from the purified fusion
protein added with Clz substrate. (B) Represents the same pair using the
coelenterazine-v (Clz-v ) substrate analog. (C) Represents TurboFP-RLuc8
pair using the Clz-v substrate. The chart represents normalized amplitude
vs. wavelength measured from purified protein with Clz-v substrate. Note
that in majority cases [e.g., (A) or (C)], typical normalized amplitude
emission of the donor is higher than the acceptor emission output,
whereas in some cases [e.g., (B)], due to efficient transfer of energy,
normalized amplitude of acceptor emission is higher than the donor
emission. (D) Represents western blot analysis of various BRET fusion
proteins made by combining mutant Renilla luciferases (such as RLuc8
and RLuc8.6) with mOrange, TagRFP, and TurboFP fluorescence acceptors.
As control, RLuc8 (RL8) protein of 35 kDa size was also shown on the right
most lane. (E) BRET ratios (denoted as A/D ratio onY -axis) are calculated
by measuring the donor and acceptor Emmax from each of these fusions in
the presence of indicated Clz (or its analog) substrate from mammalian
cells expressing the proteins. Spectral resolutions (difference between the
donor and acceptor emission peaks) are also plotted on the Z -axis (as dark
circles). One can observe an inverse relationship between the BRET ratio
measured and the spectral resolution of the BRET partners which is more
or less linear in fashion. In some cases, the BRET ratio was seen to be >1
which is theoretically not possible. This is because the values mentioned
here are the raw measured values without accounting for the C f value.
Once the C f value is added into the equation, the BRET ratios drop below
1. Note that either Clz-h or Clz-v substrate analogs can be used against
the same fusion protein to fine tune the spectral resolution. (F) Spectral
profile measured from live mammalian cells over-expressing RLuc8,
mOrange-RLuc8, TagRFP-RLuc8, and TurboFP-RLuc8 fusion proteins. Cells
over-expressing these proteins were exposed to live cell substrate
EnduRenTM (Endu) and emission profiles were imaged using IVIS
spectrum imaging system loaded with 20 nm band-pass filters between
460 and 720 nm. This arrangement provides a multiplexing opportunity,
where the same donor protein can be combined with multiple acceptors,
whose Emmax can be resolved by band-pass filter sets as indicated on
the chart.
within the same cell. BRET multiplexing was employed in one of
the GPCR studies to monitor the ubiquitination kinetics and its
involvement in receptor regulation. Exploiting the distinct spectral
emission properties of the RLuc substrates-Clz-h (Emmax 480 nm)
and Clz400 (Emmax 400 nm), Perroy et al. co-expressed RLuc-β-
arrestin and GFP2-ubiquitin along with a YFP-labeled vasopressin
receptor (V2R-YFP) (29). In this way, depending on the substrate
(Clz-h or Clz400) oxidized by RLuc, either BRET1 or BRET2 kinet-
ics can be respectively detected. Appropriate negative controls,
for instance, the use of Clz-h to detect negligible BRET trans-
fer between RLuc and GFP2 can validate the authenticity of such
experiments. Moreover, with the series of BRET systems that are
now available to us, one can recruit either a single/dual luciferase
system such as RLuc8 and RLuc8.6 with appropriate acceptor FPs
(Figure 1F), which can facilitate BRET multiplexing of three to
four candidate proteins. The ease with which this objective can be
achieved and the requirement of only a single substrate, makes it a
highly attractive option for co-lateral protein interaction studies.
MULTIPLEXED BRET OPTIONS FOR STUDYING
MULTI-PROTEIN COMPLEX
While dual-BRET techniques facilitate the concomitant mon-
itoring of two different PPIs events, elegant approaches such
as sequential RET (SRET) (30, 31), bimolecular-fluorescence
complementation-BRET (BiFC-BRET) (32, 33), complemented
donor-acceptor-RET (CODA-RET) (34), and bimolecular lumi-
nescence complementation-BiFC (BiLC-BiFC) (35, 36) have
enabled the detection of interactions between higher order protein
complexes. In the SRET technique, the three candidate proteins are
fused to either RLuc donor or one of the two FP acceptors. In such
a situation, a BRET process excites the first fluorescent acceptor,
which will now serve as a fluorescence resonance energy transfer
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(FRET) donor for the second fluorescent acceptor. Two such sys-
tems, SRET1 (RLuc-YFP-DsRed) and SRET2 (RLuc-GFP2-YFP)
utilizing Clz-h and Clz400 substrates respectively, were reported
in literature, that could detect the heterotrimerization of cannabi-
noid CB1 receptor (CB1R), dopamine D2 receptor (D2R), and
adenosine A2A receptor (A2AR) as well as the assembly of G-
protein subunits in living cells. Further, Navarro et al. successfully
demonstrated the oligomerization of Calmodulin (CaM), A2AR,
and D2R using SRET2 in live cells, which can open avenues for
screening of potential drugs that specifically target these receptor
interactions. In another study, the CB1R-D2R-A2AR interactions
were studied using a BiFC (using N- and C-termini truncated
forms of YFP) coupled with a luciferase protein to form a func-
tional BRET system (BiFC-BRET). In yet another recent literature,
a split luciferase complementation reconstituting the donor bio-
luminescence was paired to an acceptor FP to detect the BRET
signal.This technique, termed CODA-RET can be used in the study
of receptor oligomerization in presence of agonists/antagonists
as well as in drug screening. Amalgamating the above two tech-
niques, one can also employ both complemented donor along with
bimolecuar fluorescence complementation (BiLC-BiFC) to form
a functional BRET system that can explore the interaction of up
to four proteins.
BRET FOR TISSUE-SCALE IMAGING
While we have progressed so far in terms of optimizing various
BRET platforms with the aim to image PPIs non-invasively in
their natural physiological environments in vivo, it has not yet
been achieved completely. However, scientific endeavors have not
been futile. With the introduction of the intensely cooled charge
coupled device (CCD) camera-based optical imaging instrumen-
tation, the ability to detect very dim photon signals from live cells
in culture or from animal or plant tissues has become possible. To
detect signals with detectors placed outside the animal subjects,
the cells of interest present at a depth within the subject must
produce sufficient signal. Here, primarily the use of red and NIR
light signals is favored as they have lesser tissue attenuation and
thus, better penetration capacity. Therefore, overall modification
of existing assays to adapt them for non-invasive monitoring is a
challenging task. Approaching the development of a single format
imaging assay that can serve to measure PPIs from isolated sin-
gle cells as well as physiologically relevant animal/plant models,
both BRET1 and BRET2 strategies display some form of confine-
ments. Therefore, while attempting live animal BRET assays, we
have conducted serial experiments to identify an optimal BRET
assay showing satisfactory performance as a single format assay
(12, 16, 17). By now, we have introduced an ample variety of
the red light emitting BRET vectors, many of which undoubt-
edly show superior performance over the previous assays used. By
withdrawing the traditional method of BRET measurement using
a microplate reader, we adapted a method for spectral separation of
donor and acceptor signal by using black-box cooled CCD camera
macro-imager (16). An important parameter to successfully adapt
this imaging method was the use of the BRET formats with rela-
tively large spectral resolution, which allows the selection of wide
band-pass emission filters in the device. Thus the CCD camera-
based macro-imaging instrument can measure BRET signals from
lysed or live cells placed in multi-well plates. The same instrument
can then be used for BRET measurement from whole organisms
as well. A point worth noting here is that, BRET imaging from ani-
mal tissues is further complicated by the consideration of tissue
attenuation factor. To address this, a double ratio (DR) which pro-
vides a depth-independent measure of the BRET signal in animal
experiments was defined (Eq. 3) (7).
DR = BLemission
(
Acceptor λ
)
BRET × µt
(
Acceptor λ
)
BLemission(Donor λ)BRET × µt (Donor λ)
/
BLemission
(
Acceptor λ
)
donoronly × µt
(
Acceptor λ
)
BLemission(Donor λ)donoronly × µt (Donor λ)
(3)
where, µt denotes the total attenuation coefficient.
The main bottleneck of extending FRET strategy in small ani-
mal evaluation is associated with the auto-fluorescence correction
method. As light travels in and out from animal tissues, the result-
ing photon attenuation complicates the FRET ratio calculations.
In this context, the exclusion of an external photon input makes
BRET-based technologies more acquiescent for macro-scale imag-
ing of PPIs. As represented in Figure 2, we have also done proof
of principle studies by confirming the detection of the rapamycin-
dependent interaction of FKBP12 and FRB from living animals (7,
12, 17). Following the successful BRET imaging from small ani-
mal model, macro-imaging of plant tissues was also reported (37).
Using a modified electron bombardment-CCD camera coupled
with a dual-view image splitter, visualization of the constitu-
tive photomorphogenesis 1 protein (COP1) homo-dimerization
using RLuc-EYFP BRET assay was demonstrated in the rootlet and
cotyledons of tobacco seedlings in order to understand its repres-
sive activity on light regulated development in plants. The same
group had previously reported the use of a similar BRET assay
in onion epidermal cells as well as in the Arabidopsis seedlings to
study the effect of COP1 dimerization and its nuclear exclusion
on the functional activity of COP1 (38). BRET is better adapted to
plant imaging, since it circumvents the issues of photobleaching
and auto-fluorescence of photosynthetic pigments as seen in the
case of FRET. Considering careful validation of the PPIs in system-
atic, large-scale models using individual test cases, the molecular
imaging assays like BRET appear promising in the current pro-
teomic developments. So far, the major hurdle with BRET strategy
was our inability to visualize the interactions of endogenous pro-
teins. However, this is no longer an impediment, as Audet et al.
have successfully reported the measurement of BRET signals in
cell lines obtained from transgenic mice that are made to express
β2-adrenergic receptor fused to RLuc (β2AR-RLuc) and βarrestin-
2 fused to a GFP (GFP2-βarr2) (39). Even though this development
does not count for an actual detection of endogenous proteins, it
is definitely a leap in that direction. With the inception of BRET-
based quantum dots (QDs) conjugates (40, 41), in vivo imaging in
small animal models has been simplified. These new generations
of BRET probes follow a similar approach as the conventional
BRET systems and act as BRET acceptors for RLuc donor. Some
of these QDs can emit at wavelengths as high as 800 nm, enabling
the visualization of dynamic PPIs from deep tissues of small, live
animals with better resolution.
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FIGURE 2 | Bioluminescence resonance energy transfer performance in
deep tissue imaging experiments. (A) Upper panel represents mouse
images comparing improvements in the signal output from lungs. Mammalian
cells engineered for equivalent over-expression of donor alone (RLuc8 or
RLuc8.6) or BRET proteins (mOrange-RLuc8 or TurboFP-RLuc8.6) as marked,
were compared. Note the photon output values in the reference color scale
bars. Highest signal output from same number of cells placed within lungs
was noted with TurboFP-RLuc8.6 BRET protein imaged with Clz substrate.
(B) Schematic illustration of the most successful BRET format tested for
monitoring the rapamycin induced FRB-FKBP12 association.
(C) Representative bioluminescence images of nude mice with accumulated
mammalian cells in the lungs which stably over-express FRB and FKBP12
interacting partners fused to RLuc8.6 and TurboFP respectively. Cells (3×106
in 150µL PBS) were injected through the tail vein, resulting in significant
trapping in the lungs. One group of mice (n=8) was injected 2 h before cell
injection with 40µg rapamycin dissolved in 20µL DMSO and further diluted
in 130µL PBS administered through the tail vein. A second group of mice
(n=8) was injected with DMSO (20 in 130µL PBS). Two hours after cell
injection, the mice were injected i.v. with Clz substrate and sequentially
imaged using open/donor/acceptor filters. Substrate-only control mice (n=4)
were used for background subtraction. The figure is partially represented with
permission from PNAS (7).
CONCLUSION
Bioluminescence-based live cell assays are becoming increasingly
attractive in biological applications as they are rapid, fairly sensi-
tive, cost effective and easy to perform, some are even acquiescent
to high-throughput systems and offer several advantages in com-
parison to other in vitro systems. BRET has been utilized for
developing diverse live cell-based assays, many of which have now
been adapted in small animal research for tracking specific protein
functions, phosphorylation, and protease activation events as well
as screening genetic and chemical modulators. By making this
technology versatile, their scope for BRET-based molecular imag-
ing of biological events from living cells and subjects will continue
to expand.
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